Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ovid Therapeutics Inc. OVID NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.50
-15.5%

Ovid Therapeutics Inc. (OVID) is a Biotechnology company in the Healthcare sector, currently trading at $2.96. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is OVID = $3 (-15.5% upside).

Valuation: OVID trades at a trailing Price-to-Earnings (P/E) of -13.6 (S&P 500 average ~25).

Financials: revenue is $7M, +383.9%/yr average growth. Net income is $17M (loss), growing at +29%/yr. Net profit margin is -240.1% (negative). Gross margin is 95.9% (+87.8 pp trend).

Balance sheet: total debt is $13M against $131M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 10.91 (strong liquidity). Debt-to-assets is 8.9%. Total assets: $151M.

Analyst outlook: 11 / 14 analysts rate OVID as buy (79%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 20/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 49/100 (Partial), Income 10/100 (Fail).

$2.50
▼ 15.54% Downside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Ovid Therapeutics Inc., the average price target is $2.50, with a high forecast of $3.00, and a low forecast of $2.00.
Highest Price Target
$3.00
Average Price Target
$2.50
Lowest Price Target
$2.00

OVID SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 20/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 49/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OVID

✗
VALUE Fail
20/100
OVID trades at a trailing Price-to-Earnings (P/E) of -13.6 (S&P 500 average ~25). Forward PEG -0.61 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $3, implying +1.4% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
OVID: +383.9%/yr revenue is, +29%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet OVID: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 10.91 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
OVID: Gross margin is 95.9% (+87.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
49/100
Analyst outlook: 11 / 14 analysts rate OVID as buy (79%). Analyst consensus target is $3 (+1.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
OVID: Net profit margin is -240.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.243-2.72
Volume4.96M
Avg Volume (30D)2.94M
Market Cap$447.05M
Beta (1Y)-0.03
Share Statistics
EPS (TTM)-0.24
Shares Outstanding$73.74M
IPO Date2017-05-05
Employees23
CEOMargaret Alexander
Financial Highlights & Ratios
Revenue (TTM)$7.25M
Gross Profit$6.95M
EBITDA$-42.14M
Net Income$-17.41M
Operating Income$-42.44M
Total Cash$69.64M
Total Debt$13.42M
Net Debt$266K
Total Assets$150.93M
Price / Earnings (P/E)-12.3
Price / Sales (P/S)61.64
Analyst Forecast
1Y Price Target$2.50
Target High$3.00
Target Low$2.00
Upside-15.5%
Rating ConsensusBuy
Analysts Covering14
Buy 79% Hold 21% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS6904691010

Price Chart

Track all markets on TradingView
OVID
Ovid Therapeutics Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.24 52WK RANGE 2.72

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 CNTB
CNTB
Connect Biopharma Holdings Limited
$3.05
+7.77%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message